ID   HMCB
AC   CVCL_3317
SY   Human Melanoma Cell Bowes; Bowes melanoma cells; BOWES
DR   BTO; BTO:0001998
DR   CLO; CLO_0003785
DR   EFO; EFO_0002195
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-9607
DR   BioSample; SAMN10988240
DR   CCLE; HMCB_SKIN
DR   Cell_Model_Passport; SIDM00914
DR   ChEMBL-Cells; CHEMBL3308385
DR   ChEMBL-Targets; CHEMBL614824
DR   Cosmic; 724822
DR   DepMap; ACH-000931
DR   eagle-i; dartmouth.eagle-i.net/i/0000013e-d725-c97d-6a92-b95280000000
DR   GEO; GSM827473
DR   GEO; GSM887087
DR   GEO; GSM888157
DR   IGRhCellID; HMCB
DR   LiGeA; CCLE_295
DR   NCBI_Iran; C524
DR   PharmacoDB; HMCB_553_2019
DR   Wikidata; Q54889913
RX   Patent=US5010002;
RX   PubMed=1970678;
RX   PubMed=12068308;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/b/cell-lines-detail-379.html
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-109.html
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Sequence variation: NRAS p.Gln61Lys (c.181C>A) (PubMed=12068308).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.21%; Native American=0%; East Asian, North=1.87%; East Asian, South=0%; South Asian=0%; European, North=63.92%; European, South=33.99% (PubMed=30894373).
CC   Anecdotal: The Bowes cell line is famous for its use in the identification and purification of tissue-type plasminogen activator (tPA).
CC   Caution: The exact relationship between HMCB (CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,11
ST   D16S539: 13
ST   D5S818: 11,12
ST   D7S820: 11,13
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_T313 ! RPMI-7262
OI   CVCL_T314 ! RPMI-7272
OI   CVCL_T315 ! RPMI-7551
OI   CVCL_T316 ! RPMI-7781
OI   CVCL_T317 ! RPMI-7801
OI   CVCL_T318 ! RPMI-7922
OI   CVCL_2713 ! RPMI-7932
OI   CVCL_T319 ! RPMI-7962
OI   CVCL_T320 ! RPMI-7972
OI   CVCL_T321 ! RPMI-8002
OI   CVCL_T322 ! RPMI-8072
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 27
//
RX   Patent=US5010002;
RA   Levinson A., Simonsen C., Yelverton E.M.;
RT   "Human t-PA production using vectors coding DHFR protein.";
RL   Patent number US5010002, 23-Apr-1991.
//
RX   PubMed=1970678; DOI=10.1007/BF02890069;
RA   Lombardi T., Castellucci M.;
RT   "Bowes human melanoma cell line. An immunocytochemical study.";
RL   Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 58:181-183(1990).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//